Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Diabetes Ther ; 11(12): 2845-2861, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33000383

RESUMEN

INTRODUCTION: The precise blood glucose (BG) profile of hemodialysis patients is unclear, as is the effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors in hemodialysis patients with type 2 diabetes. Here, we used continuous glucose monitoring (CGM) to evaluate BG variability in these patients and to assess the efficacy of DPP-4 inhibitors, particularly during hemodialysis sessions and at nighttime (UMIN000012638). METHODS: We examined BG profiles using CGM in 31 maintenance hemodialysis patients with type 2 diabetes. Differences between patients with and without DPP-4 inhibitors (n = 15 and 16, respectively) were analyzed using a linear mixed-effects model to assess changes in glucose levels in 5-min intervals. RESULTS: The model revealed that DPP-4 inhibitor use was significantly associated with suppression of a rapid drop in glucose levels, both with and without adjustment for BG levels at the start of hemodialysis. Moreover, the model revealed that the two groups differed significantly in the pattern of changes in BG levels from 0:00 to 6:55 am. DPP-4 inhibitors suppressed the tendency for subsequent nocturnal hypoglycemia. CONCLUSIONS: This prospective observational exploratory study showed that DPP-4 inhibitors could suppress BG variability during hemodialysis sessions as well as subsequent nocturnal changes in patients with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov identifier, UMIN000012638.

2.
Mod Rheumatol ; 28(5): 897-900, 2018 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27142563

RESUMEN

We describe a 53-year-old woman with primary Sjögren's syndrome and tubulointerstitial nephritis showing distal renal tubular acidosis and Fanconi syndrome. The patient showed high serum IgM levels and positivity for antimitochondrial antibodies, although her liver function was in normal range. According to our literature review, 75% of patients with tubulointerstitial nephritis who were positive for antimitochondrial antibodies showed Fanconi syndrome, suggesting that these antibodies may directly be associated with the pathophysiology of Fanconi syndrome.


Asunto(s)
Acidosis Tubular Renal/sangre , Autoanticuerpos/sangre , Síndrome de Fanconi/sangre , Mitocondrias/inmunología , Nefritis Intersticial/sangre , Síndrome de Sjögren/sangre , Acidosis Tubular Renal/complicaciones , Acidosis Tubular Renal/inmunología , Autoanticuerpos/inmunología , Síndrome de Fanconi/complicaciones , Síndrome de Fanconi/inmunología , Femenino , Humanos , Inmunoglobulina M/sangre , Persona de Mediana Edad , Nefritis Intersticial/complicaciones , Nefritis Intersticial/inmunología , Síndrome de Sjögren/complicaciones , Síndrome de Sjögren/inmunología
3.
Clin Exp Nephrol ; 21(2): 257-265, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27216016

RESUMEN

BACKGROUND: IgA nephropathy (IgAN) is a chronic glomerular disease that causes end-stage renal disease in 20-40 % of patients within 20 years. The efficacy of tonsillectomy combined with steroid pulse (SP) administration (TSP) for clinical remission of IgAN has been reported. Particularly in Japan, TSP has been performed widely. However, the optimum method for steroid administration in TSP has not been established. METHODS: We retrospectively compared clinical remission in IgAN patients treated with tonsillectomy combined with two different steroid administration methods: (1) three courses of SP therapy and oral prednisolone administered on alternate days (group 3A; n = 25); and (2) one course of SP therapy and oral prednisolone administered on consecutive days (group 1C; n = 22). RESULTS: There was no significant difference in the clinical remission rates between the two groups at 12 (48.0 vs. 40.9 %, P = 0.77) and 24 months after starting treatment (68.0 vs. 72.7 %, P = 0.76) and at the final observation (76.0 vs. 81.8 %, P = 0.73). The mean period from starting treatment to remission of hematuria in group 3A was significantly shorter than that in group 1C (5.7 ± 4.4 vs. 9.9 ± 5.9 months, P = 0.03). Dyslipidemic patients treated for the first time with statin after the SP therapy were more present in group 3A at 24 months (P = 0.02). CONCLUSIONS: In IgAN patients, treatment of group 3A may be effective for inducing rapid remission of hematuria. Further studies are needed to establish an appropriate protocol for TSP.


Asunto(s)
Glomerulonefritis por IGA/terapia , Glucocorticoides/administración & dosificación , Metilprednisolona/administración & dosificación , Tonsilectomía , Administración Intravenosa , Administración Oral , Adulto , Terapia Combinada , Femenino , Glomerulonefritis por IGA/diagnóstico , Glomerulonefritis por IGA/inmunología , Glucocorticoides/efectos adversos , Humanos , Masculino , Metilprednisolona/efectos adversos , Quimioterapia por Pulso , Inducción de Remisión , Estudios Retrospectivos , Factores de Tiempo , Tonsilectomía/efectos adversos , Resultado del Tratamiento , Adulto Joven
4.
Hum Pathol ; 55: 164-73, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27246178

RESUMEN

IgG4-related kidney disease (IgG4-RKD) occasionally progresses to chronic renal failure and is pathologically characterized by IgG4-positive lymphoplasmacyte-rich tubulointerstitial nephritis with storiform fibrosis (bird's-eye pattern fibrosis). Although radiology reveals a heterogeneous distribution of affected areas in this disease, their true distribution within the whole kidney is still unknown because of difficulty in estimating this from needle biopsy samples. Using 5 autopsy specimens, the present study histologically characterized the distribution and components of interstitial inflammation and fibrosis in IgG4-RKD. Interstitial lymphoplasmacytic infiltration or fibrosis was observed in a variety of anatomical locations such as intracapsular, subcapsular, cortical, perivascular, and perineural regions heterogeneously in a patchy distribution. They tended to be more markedly accumulated around medium- and small-sized vessels. Storiform fibrosis was limited to the cortex. Immunostaining revealed nonfibrillar collagens (collagen IV and VI) and fibronectin predominance in the cortical lesion, including storiform fibrosis. In contrast, fibril-forming collagens (collagen I and III), collagen VI, and fibronectin were the main components in the perivascular lesion. In addition, α-smooth muscle actin-positive myofibroblasts were prominently accumulated in the early lesion and decreased with progression, suggesting that myofibroblasts produce extracellular matrices forming a peculiar fibrosis. In conclusion, perivascular inflammation or fibrosis of medium- and small-sized vessels is a newly identified pathologic feature of IgG4-RKD. Because storiform fibrosis contains mainly nonfibrillar collagens, "interstitial fibrosclerosis" would be a suitable term to reflect this. The relation between the location and components of fibrosis determined in whole kidney samples provides new clues to the pathophysiology underlying IgG4-RKD.


Asunto(s)
Enfermedades Autoinmunes/patología , Inmunoglobulina G/análisis , Riñón/patología , Nefritis Intersticial/patología , Anciano , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/metabolismo , Autopsia , Biomarcadores/análisis , Colágeno/análisis , Fibronectinas/análisis , Fibrosis , Humanos , Inmunohistoquímica , Riñón/irrigación sanguínea , Riñón/química , Riñón/inmunología , Masculino , Persona de Mediana Edad , Miofibroblastos/química , Miofibroblastos/patología , Nefritis Intersticial/inmunología , Nefritis Intersticial/metabolismo
5.
Intern Med ; 53(18): 2101-6, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25224196

RESUMEN

A 69-year-old man presented with proteinuria and hematuria. He had received total parenteral nutrition for massive small bowel resection. However, due to the iatrogenic lack of trace elements for the next four years, he developed severe copper-deficiency anemia and neutropenia. In addition, his proteinuria and kidney dysfunction worsened concurrently with the development of nephrotic syndrome and end-stage kidney disease. After receiving trace elements, the patient's anemia and neutropenia improved, and the anuria dramatically resolved. Copper-containing enzymes, including ceruloplasmin have an antioxidant activity. In patients with various types of glomerular injuries, the ceruloplasmin expression is known to be increased. Copper deficiency can worsen nephrotic syndrome by decreasing the ceruloplasmin activity, which protects the glomeruli.


Asunto(s)
Anemia/complicaciones , Ceruloplasmina/deficiencia , Fallo Renal Crónico/etiología , Síndrome Nefrótico/complicaciones , Neutropenia/complicaciones , Anciano , Anemia/metabolismo , Cobre , Humanos , Fallo Renal Crónico/metabolismo , Masculino , Síndrome Nefrótico/metabolismo , Neutropenia/metabolismo , Nutrición Parenteral Total
6.
Clin Exp Nephrol ; 18(4): 662-9, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24113782

RESUMEN

BACKGROUND: Although generally recommended for atrial fibrillation (AF) in the general population, the efficacy and safety of warfarin in hemodialysis patients remains controversial. Warfarin use in hemodialysis patients may confer an additional risk of bleeding that is not appreciated in patients without renal failure because hemodialysis patients have platelet defects and receive anticoagulation agents during dialysis. The incidence of major bleeding was reported to be higher in Japanese AF patients on warfarin therapy compared to patients in other countries, suggesting that racial differences may influence bleeding tendency. Thus, examining risks and benefits of warfarin therapy in Japanese hemodialysis patients with AF is important. METHODS: In order to determine associations between warfarin use and new ischemic stroke events, major bleeding, and all-cause mortality, a prospective cohort study of 60 Japanese hemodialysis patients with chronic sustained AF was conducted using Cox proportional modeling and propensity score matching. RESULTS: The mean patient age was 68.1 years. During 110 person-years of follow-up, 13 ischemic strokes occurred. After adjusting for CHADS2 score, warfarin use was not associated with a significant reduction in ischemic stroke events [hazard ratio (HR) 3.36; 95 % confidence interval (CI) 0.94-11.23]. Similar results were obtained after propensity score matching (HR 3.36; 95 % CI 0.67-16.66). Warfarin use was not associated with significant increases in major bleeding or all-cause mortality. CONCLUSIONS: These results suggest that warfarin may not prevent ischemic stroke in Japanese hemodialysis patients with chronic sustained AF. Adequately powered studies are needed to determine the risks and benefits of anticoagulation therapy in these patients.


Asunto(s)
Anticoagulantes/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Isquemia Encefálica/prevención & control , Fallo Renal Crónico/terapia , Diálisis Renal , Accidente Cerebrovascular/prevención & control , Warfarina/uso terapéutico , Anciano , Anticoagulantes/efectos adversos , Pueblo Asiatico , Fibrilación Atrial/diagnóstico , Fibrilación Atrial/etnología , Fibrilación Atrial/mortalidad , Isquemia Encefálica/diagnóstico , Isquemia Encefálica/etnología , Isquemia Encefálica/mortalidad , Enfermedad Crónica , Femenino , Hemorragia/inducido químicamente , Humanos , Incidencia , Japón/epidemiología , Estimación de Kaplan-Meier , Fallo Renal Crónico/diagnóstico , Fallo Renal Crónico/etnología , Fallo Renal Crónico/mortalidad , Masculino , Persona de Mediana Edad , Puntaje de Propensión , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Diálisis Renal/efectos adversos , Diálisis Renal/mortalidad , Factores de Riesgo , Accidente Cerebrovascular/diagnóstico , Accidente Cerebrovascular/etnología , Accidente Cerebrovascular/mortalidad , Factores de Tiempo , Resultado del Tratamiento , Warfarina/efectos adversos
7.
BMC Nephrol ; 14: 255, 2013 Nov 18.
Artículo en Inglés | MEDLINE | ID: mdl-24238645

RESUMEN

BACKGROUND: Dialysis disequilibrium syndrome is characterized by neurological symptoms resulting from cerebral edema, which occurs as a consequence of hemodialysis. Dialysis disequilibrium syndrome most often occurs in patients who have just started hemodialysis, during hemodialysis, or soon after hemodialysis; although it may also occur in patients who are under maintenance hemodialysis with pre-existing neurological disease. CASE PRESENTATION: A 70-year-old woman, who had been receiving maintenance hemodialysis for one year, was diagnosed with ovarian cancer by ascites cytological examination. Two years later, she reported severe headache and nausea during hemodialysis and was diagnosed with dialysis disequilibrium syndrome. Although brain images revealed mild hydrocephalus without any mass lesions, poorly differentiated adenocarcinoma cells were detected in her cerebrospinal fluid. These findings indicated that DDS was induced by neoplastic meningitis due to ovarian cancer metastasis. CONCLUSION: Neoplastic meningitis should be considered and excluded in hemodialysis patients with dialysis disequilibrium syndrome and malignancy by cytological examination of the cerebrospinal fluid even if cerebral imaging shows no obvious lesions. This is the first reported case of dialysis disequilibrium syndrome induced by neoplastic meningitis in a patient receiving maintenance hemodialysis.


Asunto(s)
Edema Encefálico/diagnóstico , Edema Encefálico/etiología , Neoplasias Encefálicas/diagnóstico , Meningitis/diagnóstico , Meningitis/etiología , Trastornos Mentales/etiología , Diálisis Renal/efectos adversos , Anciano , Neoplasias Encefálicas/complicaciones , Diagnóstico Diferencial , Femenino , Humanos , Trastornos Mentales/diagnóstico , Síndrome
8.
Clin J Am Soc Nephrol ; 8(4): 629-36, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23307880

RESUMEN

BACKGROUND AND OBJECTIVES: Previous reports of Fabry disease screening in dialysis patients indicate that α-galactosidase A activity alone cannot specifically and reliably identify appropriate candidates for genetic testing; a marker for secondary screening is required. Elevated plasma globotriaosylsphingosine is reported to be a hallmark of classic Fabry disease. The purpose of this study was to examine the usefulness of globotriaosylsphingosine as a secondary screening target for Fabry disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study screened 1453 patients, comprising 50% of the male dialysis patients in Niigata Prefecture between July 1, 2010 and July 31, 2011. Screening for Fabry disease was performed by measuring the plasma α-galactosidase A enzyme activity and the globotriaosylsphingosine concentration, by high-performance liquid chromatography. Genetic testing and genetic counseling were provided. RESULTS: A low level of plasma α-galactosidase A activity (≤4.0 nmol/h per milliliter) was observed in 47 patients (3.2%). Of these, 3 (0.2%) had detectable globotriaosylsphingosine levels. These patients all had α-galactosidase A gene mutations: one was p.Y173X and two were the nonpathogenic p.E66Q. The patient with p.Y173X started enzyme replacement therapy. Subsequent screening of his family identified the same mutation in his elder sister and her children. Genetic testing for 33 of the other 44 patients detected 7 patients with p.E66Q. Thus, the plasma lyso-Gb3 screen identified Fabry disease with high sensitivity (100%) and specificity (94.3%). CONCLUSIONS: Plasma globotriaosylsphingosine is a promising secondary screening target that was effective for selecting candidates for genetic counseling and testing and for uncovering unrecognized Fabry disease cases.


Asunto(s)
Enfermedad de Fabry/sangre , Enfermedad de Fabry/diagnóstico , Glucolípidos/sangre , Fallo Renal Crónico/sangre , Tamizaje Masivo/métodos , Diálisis Renal , Esfingolípidos/sangre , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Activación Enzimática , Enfermedad de Fabry/genética , Pruebas Genéticas , Humanos , Japón , Fallo Renal Crónico/genética , Fallo Renal Crónico/terapia , Masculino , Tamizaje Masivo/normas , Persona de Mediana Edad , Reproducibilidad de los Resultados , alfa-Galactosidasa/sangre , alfa-Galactosidasa/genética
9.
Intern Med ; 50(8): 925-9, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21498944

RESUMEN

We report a case of Churg-Strauss syndrome (CSS) complicated by severe cardiac failure and peripheral neuropathy. Two courses of methylprednisolone pulse therapy were unable to control the disease activity. Repeated intravenous administration of high-dose human immunoglobulin (IVIg) was added together with intravenous cyclophosphamide pulse therapy (IVCY), and the patient's cardiac function and neurological symptoms were gradually ameliorated without any adverse event. Although glucocorticoid and cyclophosphamide comprise the standard therapy for patients with CSS, a number of patients with severe complications appear to be resistant to such conventional treatment. IVIg is thought to be an effective therapeutic option for such patients.


Asunto(s)
Síndrome de Churg-Strauss/complicaciones , Síndrome de Churg-Strauss/terapia , Insuficiencia Cardíaca/etiología , Insuficiencia Cardíaca/terapia , Inmunoglobulinas Intravenosas/uso terapéutico , Enfermedades del Sistema Nervioso Periférico/etiología , Enfermedades del Sistema Nervioso Periférico/terapia , Enfermedad Aguda , Síndrome de Churg-Strauss/tratamiento farmacológico , Terapia Combinada , Ciclofosfamida/administración & dosificación , Progresión de la Enfermedad , Quimioterapia Combinada , Femenino , Humanos , Metilprednisolona/administración & dosificación , Persona de Mediana Edad , Resultado del Tratamiento
10.
Kidney Int ; 78(10): 1016-23, 2010 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-20720530

RESUMEN

IgG4-related disease is a recently recognized multi-organ disorder characterized by high levels of serum IgG4 and dense infiltration of IgG4-positive cells into several organs. Although the pancreas was the first organ recognized to be affected by IgG4-related disorder in the syndrome of autoimmune pancreatitis, we present here clinico-pathological features of 23 patients diagnosed as having renal parenchymal lesions. These injuries were associated with a high level of serum IgG4 and abundant IgG4-positive plasma cell infiltration into the renal interstitium with fibrosis. In all patients, tubulointerstitial nephritis was the major finding. Although 14 of the 23 patients did not have any pancreatic lesions, their clinicopathological features were quite uniform and similar to those shown in autoimmune pancreatitis. These included predominance in middle-aged to elderly men, frequent association with IgG4-related conditions in other organs, high levels of serum IgG and IgG4, a high frequency of hypocomplementemia, a high serum IgE level, a patchy and diffuse lesion distribution, a swirling fibrosis in the renal pathology, and a good response to corticosteroids. Thus, we suggest that renal parenchymal lesions actually develop in association with IgG4-related disease, for which we propose the term 'IgG4-related tubulointerstitial nephritis.'


Asunto(s)
Inmunoglobulina G/metabolismo , Nefritis Intersticial/inmunología , Nefritis Intersticial/patología , Células Plasmáticas/inmunología , Células Plasmáticas/patología , Adulto , Anciano , Anciano de 80 o más Años , Complejo Antígeno-Anticuerpo/metabolismo , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/patología , Biopsia , Femenino , Glucocorticoides/uso terapéutico , Humanos , Inmunoglobulina E/metabolismo , Riñón/inmunología , Riñón/patología , Masculino , Persona de Mediana Edad , Nefritis Intersticial/tratamiento farmacológico , Pancreatitis/inmunología , Pancreatitis/patología , Prednisolona/uso terapéutico , Estudios Retrospectivos
11.
Am J Pathol ; 161(5): 1597-606, 2002 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12414508

RESUMEN

Podocyte injury or podocyte loss in the renal glomerulus has been proposed as the crucial mechanism in the development of focal segmental glomerulosclerosis. However, it is poorly understood how podocytes respond to injury. In this study, glomerular expression of connexin43 (Cx43) gap junction protein was examined at both protein and transcript levels in an experimental model of podocyte injury, puromycin aminonucleoside (PAN) nephrosis. A striking increase in the number of immunoreactive dots with anti-Cx43 antibody was demonstrated along the glomerular capillary wall in the early to nephrotic stage of PAN nephrosis. The conspicuous change was not detected in the other areas including the mesangium and Bowman's capsule. Immunoelectron microscopy showed that the immunogold particles for Cx43 along the capillary wall were localized predominantly at the cell-cell contact sites of podocytes. Consistently, Western blotting and ribonuclease protection assay revealed a distinct increase of Cx43 protein, phosphorylation, and transcript in glomeruli during PAN nephrosis. The changes were detected by 6 hours after PAN injection. These findings indicate that the increase of Cx43 expression is one of the earliest responses that have ever been reported in podocyte injury. To show the presence of functional gap junctional intercellular communication (GJIC) in podocytes, GJIC was assessed in podocytes in the primary culture by transfer of fluorescent dye, Lucifer yellow, after a single-cell microinjection. Diffusion of the dye into adjacent cells was observed frequently in the cultured podocytes, but scarcely in cultured parietal epithelial cells of Bowman's capsule, which was compatible with their Cx43 staining. Thus, it is concluded that Cx43-mediated GJIC is present between podocytes, suggesting that podocytes may respond to injury as an integrated epithelium on a glomerulus rather than individually as a separate cell.


Asunto(s)
Conexina 43/biosíntesis , Glomérulos Renales/citología , Glomérulos Renales/metabolismo , Nefrosis/metabolismo , Regulación hacia Arriba , Animales , Comunicación Celular , Células Cultivadas , Conexina 43/análisis , Conexina 43/genética , Células Epiteliales/química , Células Epiteliales/metabolismo , Células Epiteliales/fisiología , Femenino , Uniones Comunicantes/fisiología , Inmunohistoquímica , Microscopía Inmunoelectrónica , Nefrosis/inducido químicamente , Nefrosis/patología , Proteinuria/diagnóstico , Puromicina Aminonucleósido , ARN Mensajero/análisis , Ratas , Ratas Endogámicas WKY
12.
Arch Histol Cytol ; 65(1): 83-90, 2002 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-12002613

RESUMEN

The expression and localization of the aquaporin-1 (AQP1) water channel were examined in the glomeruli of the human kidney. A ribonuclease protection assay showed the expression of AQP1 mRNA in human glomeruli but not in rat glomeruli. Western blot analysis revealed 28 kDa and 35 kDa bands corresponding to unglycosylated and glycosylated AQP1 proteins in human glomeruli. Immunoreactive AQP1 was demonstrated almost exclusively in the mesangium in the human glomeruli by immunohistochemistry. The endothelium of glomerular capillaries was only partly immunostained while podocytes and Bowman's capsule epithelia were not immunolabeled. Immunoelectron microscopy localized the immunoreactive AQP1 on the plasma membrane of mesangial cells in human glomeruli. The immouno-gold labeling was dense on the projections of mesangial cells protruding to the glomerular capillary lumen or to endothelial cells, but was sparse on other parts of the mesangial cell surface. No immunoreactivity for AQP1 was demonstrated in rat glomeruli. This study showed the distinct localization of AQP1 in the mesangial cells of human glomeruli, suggesting its role in water movement through these cells.


Asunto(s)
Acuaporinas/análisis , Glomérulos Renales/química , Animales , Acuaporinas/metabolismo , Membrana Celular/química , Membrana Celular/metabolismo , Membrana Celular/ultraestructura , Mesangio Glomerular/metabolismo , Mesangio Glomerular/ultraestructura , Humanos , Inmunohistoquímica , Glomérulos Renales/ultraestructura , Túbulos Renales Proximales/química , Túbulos Renales Proximales/metabolismo , Túbulos Renales Proximales/ultraestructura , Microscopía Inmunoelectrónica , ARN Mensajero/análisis , ARN Mensajero/metabolismo , Ratas , Ratas Endogámicas WKY
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...